Israel - hebraisk - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - סירופ - salbutamol as sulfate 2 mg / 5 ml - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types,chronic bronchitis,efmphysema.

Israel - hebraisk - Ministry of Health

teva israel ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

Israel - hebraisk - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

Israel - hebraisk - Ministry of Health

bioavenir ltd, israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

Israel - hebraisk - Ministry of Health

pharmalogic ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg / 1 ml - fulvestrant

Israel - hebraisk - Ministry of Health

teva medical marketing ltd. - cetrimide; chlorhexidine gluconate - תמיסה - cetrimide 15 %; chlorhexidine gluconate 1.5 % - chlorhexidine, combinations - chlorhexidine, combinations - antiseptic for external use.

Israel - hebraisk - Ministry of Health

bayer israel ltd - testosterone undecanoate - תמיסה להזרקה - testosterone undecanoate 250 mg/ml - testosterone - testosterone - testosterone replacement therpay in primary and secondary male hypogonadism.

Israel - hebraisk - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

Israel - hebraisk - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti